Abstract
BACKGROUND: Gadolinium nanoparticles (Gd-NP) combined with radiotherapy are investigated for radiation dose enhancement in radiotherapy treatment. Indeed, NPs concentrated in a tumor could enhance its radiosensitization. The noninvasive quantification of the NP concentration is a crucial task for radiotherapy treatment planning and post-treatment monitoring as it will determine the absorbed dose. In this work, we evaluate the achievable accuracy of in vivo SPECT-based Gd-NP organ concentration on rats. METHODS: Gd-NPs were labeled with (111)In radionuclide. SPECT images have been acquired on phantom and rats, with various Gd-NP injections. Images have been calibrated and corrected for attenuation, scatter, and partial volume effect. Image-based estimations were compared to both inductively coupled plasma mass spectrometer (ICP-MS) for Gd concentration and ex vivo organ activity measured by gamma counter. RESULTS: The accuracy for the Gd mass measurements in organ was within 10% for activity above 2 MBq or concentrations above ∼ 3-4 MBq/mL. The Gd mass calculation is based on In-Gd coefficient which defines the Gd detection limit. It was found to be in a range from 2 mg/MBq to 2 µg/MBq depending on the proportions of initial injection preparations. Measurement was also impaired by free Gd and (111)In formed during metabolic processes. CONCLUSIONS: Even if SPECT image quantification remains challenging mostly due to partial volume effect, this study shows that it has potential for the Gd mass measurements in organ. The main limitation of the method is its indirectness, and a special care should be taken if the organ of interest could be influenced by different clearance rate of free Gd and (111)In formed by metabolic processes. We also discuss the practical aspects, potential, and limitations of Gd-NP in vivo image quantification with a SPECT.